Scarica l'app Stockscreener
108.03
0.10%
-0.11
Dopo l'orario di chiusura:
107.85
-0.18
-0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$108.14
Aprire:
$109.39
Volume 24 ore:
8.83M
Relative Volume:
0.96
Capitalizzazione di mercato:
$187.72B
Reddito:
$44.33B
Utile/perdita netta:
$6.50B
Rapporto P/E:
29.06
EPS:
3.717
Flusso di cassa netto:
$7.40B
1 W Prestazione:
-1.40%
1M Prestazione:
-4.13%
6M Prestazione:
-19.22%
1 anno Prestazione:
-16.83%
Intervallo 1D:
$107.70
$110.31
Intervallo di 1 settimana:
$107.70
$112.74
Portata 52W:
$105.27
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
108.03 | 187.72B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 128.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 102.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 47.52B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott Laboratories: A Tale of Clinical Success and Market Hesitation - AD HOC NEWS
Abbott Laboratories Stock (ISIN: US0028241000) Nears 52-Week Low Amid Guidance Concerns, But Analyst - AD HOC NEWS
UBS Maintains Buy on Abbott Laboratories (ABT) March 13, 2026 - Meyka
Abbott (NYSE: ABT) outlines 2026 votes, board pay and long-term sustainability goals - Stock Titan
Abbott Launches ICRAS Tool to Assess Heart and Kidney Risks in Diabetes Patients - The Indian Practitioner
Abbott Could Get An Unexpected Lift From A Rival’s Trial - Finimize
UBS reiterates Abbott Labs stock rating on structural heart upside - Investing.com
Abbott Laboratories stock consolidates as bearish momentum continues after weak technical signals - Traders Union
Abbott Laboratories Stock (ISIN: US0028241000) Faces Pressure Amid Diagnostics Slowdown and Obesity - AD HOC NEWS
Benchmark reiterates Abbott stock rating on diabetes trial results - Investing.com
Intravenous (IV) Solutions Market Size to Reach USD 29.47 Billion by 2035 Due to the Increasing Prevalence of Chronic Diseases Globally | SNS Insider - GlobeNewswire Inc.
How The Story On Abbott Laboratories (ABT) Is Shifting As Analysts Rework Targets And Risks - Yahoo Finance
Abbott study highlights better glucose outcomes with Libre CGM in type 2 diabetes on basal insulin - MassDevice
Abbott (ABT) Showcases Positive Outcomes with FreeStyle Libre in Diabetes Management - GuruFocus
Abbott Laboratories $ABT Holdings Trimmed by Elevatus Welath Management - MarketBeat
Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & SuppliesDiversified Stocks - Yahoo Finance
Abbott’s Freedom To Work Plan And What It May Mean For NYSE ABT - simplywall.st
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management - Bolsamania
Diverging Views Emerge on Abbott Laboratories' Stock Outlook - AD HOC NEWS
Q4 Financial Results: Comparing Abbott Laboratories (NYSE:ABT) With Other Diversified Medical Devices & Supplies Stocks - Bitget
Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' - Investing News Network
Citigroup Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' – Company Announcement - Financial Times
Intuitive Surgical Upgraded to Buy by Citi — Plus Key Moves on Stryker and Abbott - 24/7 Wall St.
Van ECK Associates Corp Has $50.42 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Mackenzie Financial Corp Buys 29,440 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Franklin Resources Inc. - MarketBeat
Vitamin D Testing Market Is Going to Boom |• Abbott • Roche Diagnostics • Siemens Healthineers - openPR.com
Capital World Investors Grows Holdings in Abbott Laboratories $ABT - MarketBeat
Opening arguments begin in first Illinois trial against Abbott over its formula for premature babies - The Daily Gazette
Is Abbott Laboratories (ABT) Pricing Reflect Its Mixed Share Performance And Growth Prospects? - Yahoo Finance
MiniMed expands sensor portfolio in Europe with CE Mark for MiniMed™ 780G system with the Instinct sensor, made by Abbott - BioSpace
Capital International Sarl Buys 12,412 Shares of Abbott Laboratories $ABT - MarketBeat
Is It Time To Revisit Abbott Laboratories (ABT) After Recent Share Price Weakness? - simplywall.st
Abbott Laboratories (ABT) Announces $20 Billion Senior Notes Off - GuruFocus
Abbott Formula Linked To 'Horrible' Gut Disease, Ill. Jury Told - Law360
Abbott Laboratories Completes Major Senior Notes Offering - TipRanks
Four-Plaintiff Chicago Trial Opens Against Abbott Over Preterm Infant Formula - Law.com
Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles (NYSE:ABT) - Seeking Alpha
Vinva Investment Management Ltd Has $10.21 Million Stake in Abbott Laboratories $ABT - MarketBeat
Russell Investments Group Ltd. Purchases 92,788 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Dundas Partners LLP - MarketBeat
Abbott Laboratories Pakistan : Board Meeting - marketscreener.com
B. Metzler seel. Sohn & Co. AG Raises Stock Position in Abbott Laboratories $ABT - MarketBeat
First Trust Advisors LP Buys 810,684 Shares of Abbott Laboratories $ABT - MarketBeat
NEC Baby Formula Lawsuit & Settlement | March 2026 Update - Lawsuit Information Center
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Volatility - simplywall.st
Abbott IP chief: ‘Firms without AI policies scare me’ - Life Sciences Intellectual Property Review
Abbott Laboratories $ABT Shares Sold by Victory Capital Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.13%
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):